1.	A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer Phase: Phase III Type: Supportive care Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GWCA0958, 2009-016064-36, NCT01262651
2.	Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain Phase: Phase III Type: Supportive care Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GWCA0999, 2009-016529-32, NCT01337089
3.	Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer Phase: Phase III Type: Supportive care Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GWCA0962, 2009-016065-29, NCT01361607
4.	A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer Phase: Phase III Type: Supportive care Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GWCA1103, 2010-022905-17, NCT01424566
5.	A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GWCA1208 Part A, NCT01812603
6.	A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GWCA1208 Part B, NCT01812616